Vismodegib

• Hard capsules 150mg

Notes

1. NICE TA489: Vismodegib (Erivedge) is not recommended within its marketing authorisation for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy, in adults (November 2017).
2. NHS England (NHSE) Clinical Commissioning Policy: Vismodegib for adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas (July 2021).
   1. Vismodegib is recommended to be available as a treatment option through routine commissioning for adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas that are suitable for surgery where use of the medicine may reduce the need and extent of surgery or negate it altogether within the criteria set out in the policy.
   1. Vismodegib is unlicensed for use in these indications.